Institute of Bioengineering, École polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Institute of Materials Science & Engineering, École polytechnique fédérale de Lausanne (EPFL), Lausanne, Switzerland.
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018 Jul;10(4):e1506. doi: 10.1002/wnan.1506. Epub 2018 Jan 14.
Cancer immunotherapy has recently shown dramatic clinical success inducing durable response in patients of a wide variety of malignancies. Further improvement of the clinical outcome with immune related cancer treatment requests more exquisite manipulation of a patient's immune system with increased immunity against diseases while mitigating the toxicities. To meet this challenge, biomaterials applied to immunoengineering are being developed to achieve tissue- and/or cell-specific immunomodulation and thus could potentially enhance both the efficacy and safety of current cancer immunotherapies. Here, we review the recent advancement in the field of immunoengineering using biomaterials and their applications in promoting different modalities of cancer immunotherapies, with focus on cell-, antibody-, immunomodulator-, and gene-based immune related treatments and their combinations with conventional therapies. Challenges and opportunities are discussed in applying biomaterials engineering strategies in the development of future cancer immunotherapies. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Emerging Technologies Implantable Materials and Surgical Technologies > Nanomaterials and Implants.
癌症免疫疗法最近在诱导多种恶性肿瘤患者的持久反应方面取得了显著的临床成功。为了进一步提高免疫相关癌症治疗的临床疗效,需要更精细地调节患者的免疫系统,在增强对疾病的免疫力的同时减轻毒性。为了应对这一挑战,正在开发应用于免疫工程的生物材料,以实现组织和/或细胞特异性免疫调节,从而有可能提高当前癌症免疫疗法的疗效和安全性。在这里,我们综述了生物材料在免疫工程中的最新进展及其在促进不同类型癌症免疫疗法中的应用,重点介绍了基于细胞、抗体、免疫调节剂和基因的免疫相关治疗及其与传统疗法的结合。讨论了在开发未来癌症免疫疗法中应用生物材料工程策略所面临的挑战和机遇。本文属于以下类别:治疗方法和药物发现 > 用于肿瘤疾病的纳米医学治疗方法和药物发现 > 新兴技术 植入材料和手术技术 > 纳米材料和植入物。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2018-1-14
Acta Biomater. 2014-4
Biomater Sci. 2019-2-26
Acc Chem Res. 2020-12-15
Oncotarget. 2016-3-29
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020-9
Ther Deliv. 2013-10
Acta Biomater. 2019-2-13
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020-7
Acta Biomater. 2021-10-1
Acta Pharm Sin B. 2025-2
Pharmaceutics. 2024-1-26
Cell Death Dis. 2024-1-8
J Nanobiotechnology. 2023-9-21
Adv Sci (Weinh). 2023-6
Nano Converg. 2022-4-28
Front Bioeng Biotechnol. 2020-11-30
Biomater Sci. 2020-10-21
Front Immunol. 2020